{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:33:47Z","timestamp":1791203627315,"version":"4.2.0"},"reference-count":45,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Vancomycin (VAN) is often used to treat methicillin-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA) bacteremia despite a high incidence of microbiological failure. Recent\n            <jats:italic>in vitro<\/jats:italic>\n            analyses of \u03b2-lactams in combination with VAN demonstrated synergistic activity against MRSA. The goal of this study was to examine the impact of combination therapy with VAN and a \u03b2-lactam (Combo) on the microbiological eradication of MRSA bacteremia compared to VAN alone. This was a retrospective cohort study of patients with MRSA bacteremia who received Combo therapy or VAN alone. Microbiological eradication of MRSA, defined as a negative blood culture obtained after initiation of therapy, was used to evaluate the efficacy of each regimen. A total of 80 patients were included: 50 patients in the Combo group and 30 patients in the VAN-alone group. Microbiological eradication was achieved in 48 patients (96%) in the Combo group compared to 24 patients (80%) in the VAN-alone group (\n            <jats:italic>P<\/jats:italic>\n            = 0.021). In a multivariable model, the Combo treatment had a higher likelihood of achieving microbiological eradication (adjusted odds ratio, 11.24; 95% confidence interval, 1.7 to 144.3;\n            <jats:italic>P<\/jats:italic>\n            = 0.01). In patients with infective endocarditis (\n            <jats:italic>n<\/jats:italic>\n            = 22), 11\/11 (100%) who received Combo therapy achieved microbiological eradication compared to 9\/11 (81.8%) treated with VAN alone, but the difference was not statistically significant (\n            <jats:italic>P<\/jats:italic>\n            = 0.20). Patients with MRSA bacteremia who received Combo therapy were more likely to experience microbiological eradication of MRSA than patients who received VAN alone.\n          <\/jats:p>","DOI":"10.1128\/aac.01204-13","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T02:41:14Z","timestamp":1382409674000},"page":"102-109","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":81,"title":["\u03b2-Lactams Enhance Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus Bacteremia Compared to Vancomycin Alone"],"prefix":"10.1128","volume":"58","author":[{"given":"Thomas J.","family":"Dilworth","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jora","family":"Sliwinski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Walraven","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of New Mexico Hospital and Clinics, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e-Claude","family":"Mercier","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.06.011"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/345476"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-07"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/510386"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/520655"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05287-11"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/519470"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05473-11"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042103"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.4.515"},{"key":"e_1_3_2_15_2","volume-title":"Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr E-1472","author":"Dilworth TJ","year":"2012","unstructured":"DilworthTJSliwinski-HeathJRyanKDoddMMercierRC. 2012. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr E-1472."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-007-0934-2"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2007.08.012"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(98)00060-0"},{"key":"e_1_3_2_20_2","volume-title":"Etest for MIC determination (package insert)","author":"BioMerieux","year":"2009","unstructured":"BioMerieux. 2009. Etest for MIC determination (package insert). BioMerieux, Inc., Solna, Sweden."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1492-1502.2002"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.5.1892-1895.2006"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.11.5113-5120.2003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/80.1.27"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1047"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit052"},{"key":"e_1_3_2_27_2","first-page":"43","article-title":"Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents","volume":"47","author":"Stanley SK","year":"1998","unstructured":"StanleySKKaplanJEFauciAGordinFBartlettJGoosbyEHarringtonDMSmithMChangSAndersonJ. 1998. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Recommend. Rep. 47(RR5):43\u201382.","journal-title":"MMWR Recommend. Rep."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.22.2776"},{"key":"e_1_3_2_29_2","first-page":"79.","article-title":"301: Retrospective evaluation of the incidence of vancomycin and\/or piperacillin-tazobactam induced acute renal failure","volume":"39","author":"Hellwig T","year":"2011","unstructured":"HellwigTHammerquistRLoeckerBShieldsJ. 2011. 301: Retrospective evaluation of the incidence of vancomycin and\/or piperacillin-tazobactam induced acute renal failure. Crit. Care Med. 39(Suppl 12):79.","journal-title":"Crit. Care Med."},{"key":"e_1_3_2_30_2","first-page":"200","article-title":"714: Acute kidney injury in patients receiving concomitant vancomycin and piperacillin\/tazobactam","volume":"39","author":"Min E","year":"2011","unstructured":"MinEBoxKLaneJSanchezJCoimbraRDoucetJPotenzaBWargelL. 2011. 714: Acute kidney injury in patients receiving concomitant vancomycin and piperacillin\/tazobactam. Crit. Care Med. 39(Suppl 12):200.","journal-title":"Crit. Care Med."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390806"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/649429"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.17.1861"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-9-674"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-5-390"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.5.462"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr301"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02192-12"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05609-11"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1807.101371"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir340"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00487-10"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02354-12"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.47"},{"key":"e_1_3_2_45_2","volume-title":"Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-023","author":"Dilworth TJ","year":"2013","unstructured":"DilworthTJLeonardSMercierRC. 2013. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-023."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01152-11"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01204-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01204-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:38:06Z","timestamp":1645483086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01204-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1128\/AAC.01204-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01204-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"2013-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}